The Medicare negotiating provisions of the Build Back Better Act would lower drug spending more than the current generic competition system, according to calculations by West Health Director of Health Policy Sean Dickson. Dickson said his back-of-the-envelope math counters drug industry arguments that Medicare price negotiation legislation would have the unintended consequence of raising costs for Medicare-negotiated drugs by undermining generic competition for those drugs. Makers of biosimilars and generic drugs say that, due to the timeline for Medicare negotiation,...